MAI Capital Management - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.

Quarter-by-quarter ownership
MAI Capital Management ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$1,126,532
-16.0%
954,688
+0.3%
0.02%
-15.0%
Q2 2023$1,341,725
+110.4%
951,578
+123.8%
0.02%
+100.0%
Q1 2023$637,673
+19.3%
425,115
-6.9%
0.01%
+11.1%
Q4 2022$534,476
-9.4%
456,817
-12.5%
0.01%
-18.2%
Q3 2022$590,000
+50.9%
521,870
+110.7%
0.01%
+57.1%
Q2 2022$391,000247,7350.01%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders